Increased S100A4 expression in the vasculature of human COPD lungs and murine model of smoke-induced emphysema

Respiratory Research

Volumn 16, Issue 1, 2015, Pages

  Reimann, Sebastian ^a   Fink, Ludger ^a,b   Wilhelm, Jochen ^a   Hoffmann, Julia ^c   Bednorz, Mariola ^a   Seimetz, Michael ^a   Dessureault, Isabel ^a   Troesser, Roger ^a   Ghanim, Bahil ^d   Klepetko, Walter ^d   Seeger, Werner ^a   Weissmann, Norbert ^a   Kwapiszewska, Grazyna ^a,c  

^a JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^b Institute of Pathology and Cytology   (Germany)

^c LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

COPD; Hypoxia inducible factor; Pulmonary hypertension; RAGE; S100A4; Smooth muscle cell; Vascular remodeling

Indexed keywords

CALCIUM BINDING PROTEIN; CALVASCULIN; HYPOXIA INDUCIBLE FACTOR 1; MESSENGER RNA; SMALL INTERFERING RNA; TOBACCO SMOKE; ADVANCED GLYCATION END PRODUCT RECEPTOR; AGER PROTEIN, HUMAN; AGER PROTEIN, MOUSE; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; PROTEIN S 100; S100A4 PROTEIN, HUMAN; S100A4 PROTEIN, MOUSE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG INDUCED DISEASE; EMPHYSEMA; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LASER MICRODISSECTION; LUNG PARENCHYMA; MALE; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY ARTERY SMOOTH MUSCLE CELL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOKE INDUCED EMPHYSEMA; UPREGULATION; VASCULAR REMODELING; ADVERSE EFFECTS; ANIMAL; BINDING SITE; C57BL MOUSE; CELL CULTURE; DISEASE MODEL; DNA RESPONSIVE ELEMENT; FEMALE; GENETIC TRANSFECTION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PULMONARY EMPHYSEMA; RNA INTERFERENCE; SMOKING;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BINDING SITES; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; MALE; MICE, INBRED C57BL; MIDDLE AGED; PULMONARY ARTERY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA; RESPONSE ELEMENTS; RNA INTERFERENCE; S100 CALCIUM-BINDING PROTEIN A4; S100 PROTEINS; SMOKING; TRANSFECTION; UP-REGULATION; VASCULAR REMODELING;

EID: 84944402163     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/s12931-015-0284-5     Document Type: Article

References (45)

1. GOLDCOPD: From the Global Strategy for the Diagnosis, Management and Prevention of COPD. Updated 2014. [http://www.goldcopd.org/uploads/users/files/GOLD_Report_2014_Jun11.pdf].
2. WHO: World health statistics 2008. [www.who.int/whosis/whostat/EN_WHS08_Full.pdf].
3. United States Department of Health and Human Services. The Health Consequences of Smoking-50 Years of Progress: A Report of the Surgeon General, 2014. [http://www.surgeongeneral.gov/library/reports/50-years-ofprogress/index.html].
4. Barberà JA, Peinado VI, Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease. Eur Respir J. 2003;21:13.
5. Minai OA, Chaouat A, Adnot S. Pulmonary hypertension in COPD: epidemiology, significance, and management: pulmonary vascular disease: the global perspective. Chest. 2010;137:39S-51S.
6. Thabut G, Dauriat G, Stern JB, Logeart D, Lévy A, Marrash-Chahla R, et al. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest. 2005;127:1531-6.
7. Hoeper MM, Barberà JA, Channick RN, Hassoun PM, Lang IM, Manes A, et al. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol. 2009;30:85-96.
8. Weissmann N, Sommer N, Schermuly RT, Ghofrani HA, Seeger W, Grimminger F. Oxygen sensors in hypoxic pulmonary vasoconstriction. Cardiovasc Res. 2006;71:620-9.
9. Ghofrani HA, Voswinckel R, Reichenberger F. Hypoxia-and non-hypoxia-related pulmonary hypertension-Established and new therapies. Cardiovasc Res. 2006;72:30-40.
10. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30:2493-537.
11. Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol. 2000;88:1474-80.
12. Pathuri P, Vogeley L, Luecke H. Crystal structure of metastasis-associated protein S100A4 in the active calcium-bound form. J Mol Biol. 2008;383:62-77.
13. Ambartsumian N, Klingelhöfer J, Grigorian M, Christensen C, Kriajevska M, Tulchinsky E, et al. The metastasis-associated Mts1 (S100A4) protein could act as an angiogenic factor. Oncogene. 2001;20:4685-95.
14. Lawrie A, Spiekerkoetter E, Martinez EC, Ambartsumian N, Sheward WJ, MacLean MR, et al. Interdependent serotonin transporter and receptor pathways regulate S100A4/Mts1, a gene associated with pulmonary vascular disease. Circ Res. 2005;97:227-35.
15. Bowers RR, Manevich Y, Townsend DM, Tew KD. Sulfiredoxin redox-sensitive interaction with S100A4 and non-muscle myosin IIA regulates cancer cell motility. Biochemistry. 2012;51:7740-54.
16. Xu X, Su B, Xie C, Wei S, Zhou Y, Liu H, et al. Sonic hedgehog-Gli1 signaling pathway regulates the epithelial mesenchymal transition (EMT) by mediating a new target gene, S100A4, in pancreatic cancer cells. PLoS One. 2014;9:e96441.
17. Sohal SS, Reid D, Soltani A, Ward C, Weston S, Muller HK, et al. Evaluation of epithelial mesenchymal transition in patients with chronic obstructive pulmonary disease. Respir Res. 2011;12:130.
18. Greenway S, van Suylen RJ, Du Marchie SG, Kwan E, Ambartsumian N, Lukanidin E, et al. S100A4/Mts1 produces murine pulmonary artery changes resembling plexogenic arteriopathy and is increased in human plexogenic arteriopathy. Am J Pathol. 2004;164:253-62.
19. Kwapiszewska G, Wilhelm J, Wolff S, Laumanns I, Koenig IR, Ziegler A, et al. Expression profiling of laser-microdissected intrapulmonary arteries in hypoxia-induced pulmonary hypertension. Respir Res. 2005;6:109-25.
20. Seimetz M, Parajuli N, Pichl A, Veit F, Kwapiszewska G, Weisel FC, et al. Inducible NOS inhibition reverses tobacco-smoke-induced emphysema and pulmonary hypertension in mice. Cell. 2011;147:293-305.
21. Fink L, Kinfe T, Stein MM, Ermert L, Hanze J, Kummer W, et al. Immunostaining and laser-assisted cell picking for mRNA analysis. Lab Invest. 2000;80:327-33.
22. Fink L, Stahl U, Ermert L, Kummer W, Seeger W, Bohle RM. Rat porphobilinogen deaminase gene: a pseudogene-free internal standard for laser-assisted cell picking. BioTechniques. 1999;26:510-6.
23. Ord JJ, Streeter EH, Roberts IS, Cranston D, Harris AL. Comparison of hypoxia transcriptome in vitro with in vivo gene expression in human bladder cancer. Br J Cancer. 2005;93:346-54.
24. Hanze J, Eul BG, Savai R, Krick S, Goyal P, Grimminger F, et al. RNA interference for HIF-1alpha inhibits its downstream signalling and affects cellular proliferation. Biochem Biophys Res Commun. 2003;312:571-7.
25. Weitzenblum E, Hirth C, Ducolone A, Mirhom R, Rasaholinjanahary J, Ehrhart M. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax. 1981;36:752-8.
26. Jung SN, Yang WK, Kim J, Kim HS, Kim EJ, Yun H, et al. Reactive oxygen species stabilize hypoxia-inducible factor-1 alpha protein and stimulate transcriptional activity via AMP-activated protein kinase in DU145 human prostate cancer cells. Carcinogenesis. 2008;29:713-21.
27. Burger CD. Pulmonary hypertension in COPD: a review and consideration of the role of arterial vasodilators. COPD. 2009;6:137-44.
28. Santos S, Peinado VI, Ramírez J, Melgosa T, Roca J, Rodriguez-Roisin R, et al. Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD. Eur Respir J. 2002;19:632-8.
29. Barberà JA, Riverola A, Roca J, Ramirez J, Wagner PD, Ros D, et al. Pulmonary vascular abnormalities and ventilation-perfusion relationships in mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1994;149:423-9.
30. Kriajevska M, Tarabykina S, Bronstein I, Maitland N, Lomonosov M, Hansen K, et al. Metastasis-associated Mts1 (S100A4) protein modulates protein kinase C phosphorylation of the heavy chain of nonmuscle myosin. J Biol Chem. 1998;273:9852-6.
31. Hoffmann J, Wilhelm J, Marsh LM, Ghanim B, Klepetko W, Kovacs G, et al. Distinct differences in gene expression patterns in pulmonary arteries of patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis with pulmonary hypertension. Am J Respir Crit Care Med. 2014;190:98-111.
32. Köhl R, Zhou J, Brüne B. Reactive oxygen species attenuate nitric-oxidemediated hypoxia-inducible factor-1alpha stabilization. Free Radic Biol Med. 2006;40:1430-42.
33. Horiuchi A, Hayashi T, Kikuchi N, Hayashi A, Fuseya C, Shiozawa T, et al. Hypoxia upregulates ovarian cancer invasiveness via the binding of HIF-1a to a hypoxia-induced, methylation-free hypoxia response element of S100A4 gene. Int J Cancer. 2012;131:1755-67.
34. Weitzenblum E, Schrijen F, Mohan-Kumar T, Colas des Francs V, Lockhart A. Variability of the pulmonary vascular response to acute hypoxia in chronic bronchitis. Chest. 1988;94:772-8.
35. Wright JL, Cosio M, Churg A. Animal models of chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol. 2008;295:L1-15.
36. Springer J, Fischer A. Substance P-induced pulmonary vascular remodelling in precision cut lung slices. Eur Respir J. 2003;22:596-601.
37. Brüne B, Zhou J. Hypoxia-inducible factor-1alpha under the control of nitric oxide. Methods Enzymol. 2007;435:463-78.
38. Guo L, Li L, Wang W, Pan Z, Zhou Q, Wu Z. Mitochondrial reactive oxygen species mediates nicotine-induced hypoxia-inducible factor-1a expression in human non-small cell lung cancer cells. Biochim Biophys Acta. 2012;1822:852-61.
39. Baglole CJ, Bushinsky SM, Garcia TM, Kode A, Rahman I, Sime PJ, et al. Differential induction of apoptosis by cigarette smoke extract in primary human lung fibroblast strains: implications for emphysema. Am J Physiol Lung Cell Mol Physiol. 2006;291:L19-29.
40. Huang MF, Lin WL, Ma YC. A study of reactive oxygen species in mainstream of cigarette. Indoor Air. 2005;15:135-40.
41. Zhang Q, Tang X, Zhang ZF, Velikina R, Shi S, Le AD. Nicotine induces hypoxia-inducible factor-1alpha expression in human lung cancer cells via nicotinic acetylcholine receptor-mediated signaling pathways. Clin Cancer Res. 2007;13:4686-94.
42. Meloche J, Courchesne A, Barrier M, Carter S, Bisserier M, Paulin R, et al. Critical role for the advanced glycation end-products receptor in pulmonary arterial hypertension etiology. J Am Heart Assoc. 2013;2:e005157.
43. Zabini D, Crnkovic S, Xu H, Tscherner M, Ghanim B, Klepetko W, et al. High-mobility group box-1 induces vascular remodelling processes via c-Jun activation. J Cell Mol Med. 2015;19:1151-61.
44. Dempsie Y, Nilsen M, White K, Mair KM, Loughlin L, Ambartsumian N, et al. Development of pulmonary arterial hypertension in mice over-expressing S100A4/Mts1 is specific to females. Respir Res. 2011;12:159.
45. Cheng DT, Kim DK, Cockayne DA, Belousov A, Bitter H, Cho MH, et al. Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;188:948-57.